Biopharma | December 04, 2025
Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Subscribe To Our Newsletter & Stay Updated
